Photo from Nicolas Duployez/X
Aug 19, 2024, 10:07
Nicolas Duployez: A 4-gene prognostic model stratified OS outcomes with VEN-AZA treatment in AML
Nicolas Duployez, Molecular Biologist at Lille University Hospital, shared on X about a recent paper by Hartmut Döhner et al. titled “Genetic Risk Stratification and Outcomes Among Treatment-Naive Patients With AML Treated With Venetoclax and Azacitidine” published in Blood Journals.
Authors: Hartmut Döhner et al.
“ELN 2017/2022 prognostic classifiers did not adequately stratify OS outcomes for AML patients treated with VEN-based regimens.
A 4-gene prognostic model (TP53, FLT3-ITD, NRAS, and KRAS) stratified OS outcomes with VEN-AZA treatment in AML.”
Source: Nicolas Duployez/X
AML
Andre Schuh
Andrew Wei
Blood Journals
Brenda Chyla
Brian Jonas
cancer
Christian Récher
Courtney DiNardo
Daniel Pollyea
FLT3-ITD
Grace Ku
Hartmut Döhner
Jalaja Potluri
Keith Pratz
Lille University Hospital
Michael Thirman
Monique Dail
Nicolas Duployez
NRAS
OncoDaily
Oncology
OS
Sunil Babu
TP53
VEN-AZA treatment
Vinod Pullarkat
Xiaotong Li
Yan Sun
Zihuan Liu
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 1, 2024, 19:12
Nov 1, 2024, 17:46
Nov 1, 2024, 17:41
Nov 1, 2024, 17:27